M&A / Deals Jazz orchestrates a $4bn cancer alliance with AbCellera PharmaphorumJazz Pharma has made a big move into T-cell engagers (TCEs) for solid tumours, via an alliance with Canadian biotech AbCellera.OncologyRead full story pharminent June 17, 2026 (Last updated: June 17, 2026) Pharmaphorum Jazz Pharma has made a big move into T-cell engagers (TCEs) for solid tumours, via an alliance with Canadian biotech AbCellera. Oncology Read full story Post navigation Previous: Edgewise slides as cardiomyopathy challenger to BMS, Cytokinetics falls shortNext: uniQure sets course to US filing for Huntington gene therapy Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
